Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Lung Cancer. 2009 May 26;67(3):366. doi: 10.1016/j.lungcan.2009.04.019

Fig. 2.

Fig. 2

This figure illustrates the impact of varying the prevalence of malignant mediastinal lymph nodes (P_LN) on the cost of patient management. The costs of EUS FNA (◆) and EUS FNA+EBUS FNA (▼) are equivalent ($18,170) when P_LN is 32.9%.